|
Review
The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
Sung-Yong Kim, Sung Hwa Bae, Soo-Mee Bang, Ki-Seong Eom, Junshik Hong, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Min Kyoung Kim, Soo-Jeong Kim, Yeung-Chul Mun, Seung-Hyun Nam, Jinny Park, Jong-Ho Won, Chul Won Choi
Korean J Intern Med. 2021;36(1):45-62. Published online December 4, 2020
In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional som..
|
|
|
Review
Recent insights regarding the molecular basis of myeloproliferative neoplasms
Mi-Ae Jang, Chul Won Choi
Korean J Intern Med. 2020;35(1):1-11. Published online November 29, 2019
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal disorders characterized by the overproduction of mature blood cells that have an increased risk of thrombosis and progression to acute myeloid leukemia. Next-generation sequencing studies have provided key insights regarding the..
|
|
|
Hemato-oncology / Review
Recent advances in the diagnosis and management of primary myelofibrosis
Katsuto Takenaka, Kazuya Shimoda, Koichi Akashi
Korean J Intern Med. 2018;33(4):679-690. Published online April 20, 2018
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) in which dysregulation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathways is the major pathogenic mechanism. Most patients with PMF carry a driver mutation in the JAK2, MPL (my..
|
|
|
Hemato-oncology / Review
Guidelines for the management of myeloproliferative neoplasms
Chul Won Choi, Soo-Mee Bang, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Soo-Jeong Kim, Yeo-Kyeoung Kim, Jinny Park, Jong-Ho Won
Korean J Intern Med. 2015;30(6):771-788. Published online October 30, 2015
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysio..
|
|
|
